Webinar

Medicare and Employee Benefits

Thu, Feb 17, 2022 2:00 PM – 3:00 PM CST
Presented by Benefit Comply

Employee benefits managers face new issues as the workforce ages. As more active employees and their spouses become Medicare eligible, it is more important than ever for employer to understand how Medicare interacts with employer sponsored benefits. This webinar will cover employee eligibility issues including HSA eligibility, Medicare Secondary Payer (MSP) Rules that prohibit employers form incenting employees to take Medicare, the COBRA Medicare penalty trap some former employee face, and more. You don’t have to be a member of AARP to join (and learn a lot) from this webinar.

Registration

About the Author

INSURICA
INSURICA

Share This Story

Stay Updated

Subscribe to the INSURICA blog and receive the latest news direct to your inbox.

Related Blogs

Fiduciary Responsibilities for Employer Health Plans: What Employers Should Know Now

March 6th, 2026|Blog, Employee Benefits|

When employers think about fiduciary responsibility, retirement plans often come to mind first. But recent developments make it clear that fiduciary duties also matter—sometimes significantly—when it comes to employer-sponsored health and welfare plans.

The New Era of Mental Health Parity Enforcement in 2026

March 5th, 2026|Blog, Employee Benefits|

Federal agencies have made mental health parity enforcement a top priority in 2026, and employers sponsoring group health plans are feeling the impact. Regulators are no longer satisfied with high‑level assurances that plans comply with the Mental Health Parity and Addiction Equity Act (MHPAEA). Instead, they expect detailed, data‑driven documentation showing that mental health and substance‑use‑disorder benefits are truly comparable to medical and surgical benefits. This includes not only the written plan design but also how rules are applied in real‑world scenarios.

The 2026 Specialty Drug Surge: What Employers Need to Prepare For

March 3rd, 2026|Blog, Employee Benefits|

Specialty drugs have been a major cost driver for years, but 2026 marks a significant shift in both scale and urgency. With GLP 1 medications expanding into new indications, gene therapies entering the market at record pace, and oncology drugs continuing to rise in both cost and utilization, specialty medications are projected to account for more than 60% of total pharmacy spending this year. That’s a dramatic change for employers, especially considering that specialty drugs represent fewer than 5% of total prescriptions.

Go to Top